SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer ...
The SWOG S1602 trial ( NCT03091660) evaluated the noninferiority of the Tokyo versus TICE BCG strains, as well as testing the superiority of T cell priming with intradermal BC before intravesical ...
Novel immunotherapies and chemotherapies hold promise as non-surgical salvage options. Recent advances in our understanding of systemic immunotherapy, however, have transformed the management of ...
Whether BCG strains other than BCG TICE are safe and effective for treating high-grade NMIBC warrants rigorous testing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results